Literature DB >> 9562667

Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.

R J Barohn1, D S Saperstein.   

Abstract

Acute and chronic inflammatory demyelinating polyneuropathies represent an important group of disorders. Although the acute form is more common, all clinical neurologists will eventually encounter patients with these disorders. Acute inflammatory demyelinating polyneuropathy, or Guillain-Barré syndrome, is the most common cause of acute generalized weakness. Chronic inflammatory demyelinating polyneuropathy, characterized by progressive or relapsing weakness, is important to recognize because it represents a significant number of all initially undiagnosed acquired neuropathies. There are a variety of reasonable therapies available for both of these acquired demyelinating neuropathies. Recently much has been learned about pathogenesis and treatment. This review describes the clinical presentations, laboratory studies, diagnostic criteria, treatment, and prognosis for each disorder.

Entities:  

Mesh:

Year:  1998        PMID: 9562667     DOI: 10.1055/s-2008-1040861

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  9 in total

1.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

2.  Guillain-Barre Syndrome in a Patient with Primary Extranodal Intestinal Non-Hodgkin's Lymphoma: Paraneoplastic, Drug Induced or Coincidental?

Authors:  Aslı Kiyat Atamer; Kerem Okutur; Erdem Tüzün; Barış Hasbal; Ari Boyaciyan; Yakup Krespi; Gökhan Demir
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

Review 3.  Guillain-Barré syndrome and variants.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-02-19       Impact factor: 3.806

4.  Pattern-recognition approach to neuropathy and neuronopathy.

Authors:  Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2013-05       Impact factor: 3.806

5.  Guillain-barré syndrome.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 6.  Vaccines and Guillain-Barré syndrome.

Authors:  Penina Haber; James Sejvar; Yann Mikaeloff; Frank DeStefano
Journal:  Drug Saf       Date:  2009       Impact factor: 5.228

7.  Severe Acute Axonal Neuropathy Induced by Ciprofloxacin: A Case Report.

Authors:  Cyprian Popescu
Journal:  Case Rep Neurol       Date:  2018-05-30

8.  Guillain-Barré syndrome and COVID-19: association or coincidence.

Authors:  Aislinn Gale; Suganya Sabaretnam; Asher Lewinsohn
Journal:  BMJ Case Rep       Date:  2020-11-30

9.  Post Vaccination Guillain Barre Syndrome: A Case Report.

Authors:  Muhammad Wajih Ullah; Aisha Qaseem; Afshan Amray
Journal:  Cureus       Date:  2018-04-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.